Pain & Central Nervous System Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pain & Central Nervous System Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Ankylosing Spondylitis
New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
November 19th, 2007
More than half of patients receiving monthly subcutaneous (SC) injections of golimumab (CNTO 148) 50 mg and 100 mg experienced significant and sustained improvements in the signs and symptoms of active ankylosing spondylitis, according to Phase 3 study results presented at the American College of Rheumatology (ACR) annual meeting. At week 14 of the study, 59 percent of patients receiving golimumab 50 mg and 60 percent of patients receiving golimumab 100 mg achieved at least 20 percent improvement in the Assessment in Ankylosing Spondylitis criteria (ASAS 20) compared with 22 percent of patients receiving placebo (P < 0.001). Investigators also reported that study subjects receiving...
Source: Pain & Central Nervous System Week (2007-11-19)
|
|
|
